Serum progastrin-releasing peptide levels followed by whole-body positron emission tomography detects early recurrence of small-cell lung cancer.
A 65-year-old male smoker with severe COPD was diagnosed with limited-stage small-cell lung cancer. After receiving cisplatin/irinotecan, serum progastrin-releasing peptide (ProGRP) levels decreased to within the reference values and the lesions were markedly reduced in size. A whole-body 18F-fluorodeoxyglucose PET (FDG-PET) scan confirmed complete remission. During follow up, serum ProGRP levels increased, and a whole-body FDG-PET scan detected recurrence at the hilar lymph node that had been negative on CT. Complete remission was again achieved with second-line chemotherapy (cisplatin/etoposide) and local irradiation to the hilar lymph node. Monitoring serum ProGRP levels, followed by whole-body FDG-PET when indicated, may improve the clinical management of patients with small-cell lung cancer after initial complete remission.
Yamaguchi
Hiroyuki
H
Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan.
Soda
Hiroshi
H
Kitazaki
Takeshi
T
Nakano
Hirofumi
H
Fujino
Satoru
S
Nakamura
Yoichi
Y
Kohno
Shigeru
S
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D018288:Carcinoma, Small Cell / Q000097:blood / Q000000981:diagnostic imaging / Q000473:pathology; D018450:Disease Progression; D017809:Fatal Outcome; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000473:pathology; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000000981:diagnostic imaging / Q000473:pathology; D010446:Peptide Fragments / Q000097:blood*; D010455:Peptides / Q000097:blood*; D049268:Positron-Emission Tomography / Q000379:methods*; D011994:Recombinant Proteins / Q000097:blood
D014408:Biomarkers, Tumor; D010446:Peptide Fragments; D010455:Peptides; D011994:Recombinant Proteins; C087079:pro-gastrin-releasing peptide (31-98)